Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

MIT

MIT Inventing a Machine That Manufactures Pharmaceuticals in a New Way

Innovation Ahead signBoston, MA, June 2, 2016 — WBUR’s Martha Beinger reports on Kaiser Health News that in a lab at the Massachusetts Institute of Technology (MIT), all the work that happens in a vast pharmaceutical manufacturing plant happens in a device the size of your kitchen refrigerator.

And it’s fast.  This prototype machine produces 1,000 pills in 24 hours, faster than it can take to produce some batches in a factory.

Allan Myerson, a professor of chemical engineering at MIT and a leader of the effort, says it could become eventually an option for anyone who makes medications, which typically require a lengthy and complex process of crystallization.

“We’re giving them an alternative to traditional plants and we’re reducing the time it takes to manufacturer a drug,” he said. Continue reading

MIT Study Faults U.S. for Risking Nation’s Innovation, R&D Edge

Washington, DC, April 28, 2015 ― Robert McMillan reports in The Wall Street Journal that, with Asia emerging as the world’s powerhouse of research and development (R&D), the United States risks losing its position as a magnet for the world’s best academic researchers, according to a report by the Massachusetts Institute of Technology.

The MIT authors warned that the U.S. government was spending an ever-smaller percentage of its budget on basic R&D.  Though the U.S. leads the world in total R&D outlays, Europe and Asia have been raising their government investment.

The report, titled “The Future Postponed: Why Declining Investment in Basic Research Threatens a U.S. Innovation Deficit,” lays out the funding challenges for research in 15 areas, including the life science areas of Alzheimer’s disease, infectious diseases and synthetic biology. Continue reading